Drug Resistance Updates, Год журнала: 2025, Номер unknown, С. 101264 - 101264
Опубликована: Июнь 1, 2025
Язык: Английский
Drug Resistance Updates, Год журнала: 2025, Номер unknown, С. 101264 - 101264
Опубликована: Июнь 1, 2025
Язык: Английский
Kinases and Phosphatases, Год журнала: 2025, Номер 3(2), С. 7 - 7
Опубликована: Апрель 12, 2025
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive neoplastic malignancy characterised by the accumulation of multiple oncogenic and epigenetic alterations in haematopoietic precursors leading to their uncontrolled proliferation bone marrow. For many years it has been established that occurrence activating mutations, transcription factors expression, impairment cell cycle regulators, hyperactivation NOTCH1 signalling play prominent roles pathogenesis this disease. Recently, introduction high-resolution screening next-generation sequencing platforms revealed progenitors accumulate additional affecting protein kinase signalling, translation, control mechanisms, providing novel attractive targets for therapy. While contributions direct genomic events are well understood as causative agents hyperactive pathways, rewiring cascades via DNA methylation, histone post-translational modifications, non-coding miRNAs remains less explored. In review, we provide perspectives on regulatory aspects heterogeneity T-ALL therapeutic outcomes.
Язык: Английский
Процитировано
0Drug Resistance Updates, Год журнала: 2025, Номер unknown, С. 101264 - 101264
Опубликована: Июнь 1, 2025
Язык: Английский
Процитировано
0